We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current RCKT market cap is 1.95B. The company's latest EPS is USD -2.7136 and P/E is -0.03.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -58.49M | -69.08M | -62.19M | -68.76M | -65.43M |
| Net Income | -57.76M | -66.72M | -58.34M | -65.7M | -61.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -76.15M | -134.3M | -167.25M | -224.34M | -259.66M |
| Net Income | -77.27M | -139.7M | -169.07M | -221.86M | -245.6M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 417.27M | 551.81M | 514.76M | 461.78M | 598.76M |
| Total Liabilities | 49.95M | 62.12M | 55.88M | 58.81M | 57.68M |
| Total Equity | 367.31M | 489.69M | 458.88M | 402.97M | 541.09M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 372.12M | 590.82M | 497.02M | 551.81M | 566.34M |
| Total Liabilities | 64.82M | 87.31M | 42.3M | 62.12M | 73.77M |
| Total Equity | 307.3M | 503.52M | 454.72M | 489.69M | 492.57M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -122.12M | -178.14M | -57.56M | -108.43M | -165.58M |
| Investing | 39.26M | -69.33M | -36.72M | -5.52M | 42.74M |
| Financing | 46.85M | 155.29M | 18.34M | 18.53M | 208.01M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -64.66M | -74.64M | -121.16M | -178.14M | -194.92M |
| Investing | -39.01M | -96.59M | 18.85M | -69.33M | -98.07M |
| Financing | 177.79M | 282.99M | 37.68M | 155.29M | 208.4M |
| Market Cap | 1.95B |
| Price to Earnings Ratio | -0.03 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.15 |
| Price to Book Ratio | 0.02 |
| Dividend Yield | - |
| Shares Outstanding | 90.5M |
| Average Volume (1 week) | 787.26k |
| Average Volume (1 Month) | 699.72k |
| 52 Week Change | 20.54% |
| 52 Week High | 32.525 |
| 52 Week Low | 14.89 |
| Spread (Intraday) | 1.11 (4.96%) |
| Company Name | Rocket Pharmaceuticals Inc |
| Address |
300 delaware avenue wilmington, delaware 19801 |
| Website | https://www.rocketpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
